Cormorant Asset Management’s Vaxcyte PCVX Stock Holding History

Cormorant Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.91M	Sell	50,000 -50,000	-50%	-$2.72M	0.15%	48
2026 Q1	$5.81M	Sell	100,000 -25,000	-20%	-$1.36M	0.29%	44
2025 Q4	$5.77M	Sell	125,000 -50,000	-29%	-$2.24M	0.27%	33
2025 Q3	$6.3M	Hold	175,000	–	–	0.43%	34
2025 Q2	$5.69M	Hold	175,000	–	–	0.42%	36
2025 Q1	$6.61M	Sell	175,000 -250,000	-59%	-$20M	0.5%	35
2024 Q4	$34.8M	Sell	425,000 -575,000	-58%	-$57.1M	1.91%	14
2024 Q3	$114M	Sell	1,000,000 -100,000	-9%	-$9.01M	6.06%	2
2024 Q2	$83.1M	Buy	1,100,000 +415,000	+61%	+$28.2M	4.8%	4
2024 Q1	$46.8M	Buy	685,000 +20,000	+3%	+$1.38M	2.05%	14
2023 Q4	$41.8M	Hold	665,000	–	–	1.99%	14
2023 Q3	$33.9M	Hold	665,000	–	–	1.98%	13
2023 Q2	$33.2M	Buy	665,000 +390,000	+142%	+$18.5M	1.86%	11
2023 Q1	$10.3M	Sell	275,000 -50,000	-15%	-$2.12M	0.68%	38
2022 Q4	$15.6M	Buy	+325,000	New	+$12.8M	1.04%	31

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Cormorant Asset Management's PCVX Position: Q2 2026 in Review

Cormorant Asset Management reduced its Vaxcyte (PCVX) stake by 50% in Q2 2026, selling an estimated $2.72M and leaving 50,000 shares worth $2.91M. The position accounts for 0.15% of the portfolio, ranked #48.

Cormorant Asset Management first reported a position in PCVX in Q4 2022 and has held it in 15 quarters since. The position peaked at $114M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Cormorant Asset Management held 50,000 shares of Vaxcyte worth $2.91M as of Q2 2026.
Cormorant Asset Management sold 50,000 Vaxcyte shares in Q2 2026, an estimated $2.72M.
Vaxcyte made up 0.15% of Cormorant Asset Management's portfolio in Q2 2026, its #48 holding.
Cormorant Asset Management first reported a position in Vaxcyte in Q4 2022 and has held it in 15 quarters since.
Cormorant Asset Management's Vaxcyte position peaked at $114M in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.